News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug
February 17, 2017
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
San Diego/Hangzhou-based Denovo Biopharma plans to launch a biomarker driven global Phase III clinical trial for its lead drug DB102 as a first line treatment for diffuse large B-cell lymphoma (DLBCL) patients this year.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ELEMENT
Innovation, Resilience, and the Future of Global Manufacturing
October 30, 2025
·
1 min read
·
BioSpace Insights
CAR-T
Kyverna’s CAR T Therapy Sets ‘New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials
October 30, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie
Clinical research
BridgeBio Shares Pop Again as Phase III Thyroid Drug Exceeds Investor Expectations
October 29, 2025
·
3 min read
·
Annalee Armstrong
